Baseline clinical and biochemical characteristics of 82 PD patients and 87 healthy subjects
| Parameters . | PD patients (n = 82) . | Healthy subjects (n = 87) . |
|---|---|---|
| Age (years) | 64 ± 14 | 26 (±5) |
| Male (%) | 66 | 33 |
| Female (%) | 44 | 67 |
| Davies score (%) | ||
| Low comorbidity risk | 28 | – |
| Medium comorbidity risk | 58 | |
| High comorbidity risk | 14 | |
| Diabetes mellitus (%) | 25 | – |
| History of cardiovascular disease (%) | 29 | – |
| Vintage (months)a | 28 (7–101) | – |
| Kt/Vurea | 2.2 (1.8–2.5) | – |
| Residual GFR (mL/min/1.73 m2) | 3 (1–4) | – |
| Haemoglobin (g/L) | 119 ± 11 | 137 ± 14 |
| P-albumin (g/L) | 32 ± 5 | 41 ± 3 |
| hs C-reactive protein (mg/L) | 4.1 (1.4–10.6) | – |
| Delta-He (pg) | 2.3 (0.9–3.9) | 3.1 (2.3–3.7) |
| Ret-He (pg) | 34.0 (32.4–36.3) | 33.8 (32.0–36.0) |
| S-ferritin (μg/L) | 299 (179–538) | 42 (23–82) |
| Transferrin saturation (%) | 26 (19–35) | – |
| EHRI (IU/kg/g/L Hb per week) | 0.65 (0.26–0.89) | – |
| P-interleukin-6 (pg/mL) | 6.5 (3.9–9.6) | NA |
| P-tumour necrosis factor (pg/mL) | 16.7 (14.7–18.6) | NA |
| P-parathyroid hormone (pg/mL) | 281 (146–443) | NA |
| Medication use (%) | ||
| Antihypertensive drugs | 91 | – |
| Statins | 49 | |
| Antiaggregants/anticoagulants | 49 | |
| Erythropoietin-stimulating agents | 93 | |
| Phosphate binders | 72 | |
| Vitamin D receptor activators | 83 | |
| Calcimimetics | 12 | |
| Immunosuppressant drugs | 13 | |
| Iron supplementation (intravenous or oral) | 32 | |
| Parameters . | PD patients (n = 82) . | Healthy subjects (n = 87) . |
|---|---|---|
| Age (years) | 64 ± 14 | 26 (±5) |
| Male (%) | 66 | 33 |
| Female (%) | 44 | 67 |
| Davies score (%) | ||
| Low comorbidity risk | 28 | – |
| Medium comorbidity risk | 58 | |
| High comorbidity risk | 14 | |
| Diabetes mellitus (%) | 25 | – |
| History of cardiovascular disease (%) | 29 | – |
| Vintage (months)a | 28 (7–101) | – |
| Kt/Vurea | 2.2 (1.8–2.5) | – |
| Residual GFR (mL/min/1.73 m2) | 3 (1–4) | – |
| Haemoglobin (g/L) | 119 ± 11 | 137 ± 14 |
| P-albumin (g/L) | 32 ± 5 | 41 ± 3 |
| hs C-reactive protein (mg/L) | 4.1 (1.4–10.6) | – |
| Delta-He (pg) | 2.3 (0.9–3.9) | 3.1 (2.3–3.7) |
| Ret-He (pg) | 34.0 (32.4–36.3) | 33.8 (32.0–36.0) |
| S-ferritin (μg/L) | 299 (179–538) | 42 (23–82) |
| Transferrin saturation (%) | 26 (19–35) | – |
| EHRI (IU/kg/g/L Hb per week) | 0.65 (0.26–0.89) | – |
| P-interleukin-6 (pg/mL) | 6.5 (3.9–9.6) | NA |
| P-tumour necrosis factor (pg/mL) | 16.7 (14.7–18.6) | NA |
| P-parathyroid hormone (pg/mL) | 281 (146–443) | NA |
| Medication use (%) | ||
| Antihypertensive drugs | 91 | – |
| Statins | 49 | |
| Antiaggregants/anticoagulants | 49 | |
| Erythropoietin-stimulating agents | 93 | |
| Phosphate binders | 72 | |
| Vitamin D receptor activators | 83 | |
| Calcimimetics | 12 | |
| Immunosuppressant drugs | 13 | |
| Iron supplementation (intravenous or oral) | 32 | |
Categorical data are shown as percentage; continuous data as mean ± SD or median and interquartile range (25th and 75th percentiles) as appropriate.
NA, not available.
aVintage denotes preceding total time on PD.
Baseline clinical and biochemical characteristics of 82 PD patients and 87 healthy subjects
| Parameters . | PD patients (n = 82) . | Healthy subjects (n = 87) . |
|---|---|---|
| Age (years) | 64 ± 14 | 26 (±5) |
| Male (%) | 66 | 33 |
| Female (%) | 44 | 67 |
| Davies score (%) | ||
| Low comorbidity risk | 28 | – |
| Medium comorbidity risk | 58 | |
| High comorbidity risk | 14 | |
| Diabetes mellitus (%) | 25 | – |
| History of cardiovascular disease (%) | 29 | – |
| Vintage (months)a | 28 (7–101) | – |
| Kt/Vurea | 2.2 (1.8–2.5) | – |
| Residual GFR (mL/min/1.73 m2) | 3 (1–4) | – |
| Haemoglobin (g/L) | 119 ± 11 | 137 ± 14 |
| P-albumin (g/L) | 32 ± 5 | 41 ± 3 |
| hs C-reactive protein (mg/L) | 4.1 (1.4–10.6) | – |
| Delta-He (pg) | 2.3 (0.9–3.9) | 3.1 (2.3–3.7) |
| Ret-He (pg) | 34.0 (32.4–36.3) | 33.8 (32.0–36.0) |
| S-ferritin (μg/L) | 299 (179–538) | 42 (23–82) |
| Transferrin saturation (%) | 26 (19–35) | – |
| EHRI (IU/kg/g/L Hb per week) | 0.65 (0.26–0.89) | – |
| P-interleukin-6 (pg/mL) | 6.5 (3.9–9.6) | NA |
| P-tumour necrosis factor (pg/mL) | 16.7 (14.7–18.6) | NA |
| P-parathyroid hormone (pg/mL) | 281 (146–443) | NA |
| Medication use (%) | ||
| Antihypertensive drugs | 91 | – |
| Statins | 49 | |
| Antiaggregants/anticoagulants | 49 | |
| Erythropoietin-stimulating agents | 93 | |
| Phosphate binders | 72 | |
| Vitamin D receptor activators | 83 | |
| Calcimimetics | 12 | |
| Immunosuppressant drugs | 13 | |
| Iron supplementation (intravenous or oral) | 32 | |
| Parameters . | PD patients (n = 82) . | Healthy subjects (n = 87) . |
|---|---|---|
| Age (years) | 64 ± 14 | 26 (±5) |
| Male (%) | 66 | 33 |
| Female (%) | 44 | 67 |
| Davies score (%) | ||
| Low comorbidity risk | 28 | – |
| Medium comorbidity risk | 58 | |
| High comorbidity risk | 14 | |
| Diabetes mellitus (%) | 25 | – |
| History of cardiovascular disease (%) | 29 | – |
| Vintage (months)a | 28 (7–101) | – |
| Kt/Vurea | 2.2 (1.8–2.5) | – |
| Residual GFR (mL/min/1.73 m2) | 3 (1–4) | – |
| Haemoglobin (g/L) | 119 ± 11 | 137 ± 14 |
| P-albumin (g/L) | 32 ± 5 | 41 ± 3 |
| hs C-reactive protein (mg/L) | 4.1 (1.4–10.6) | – |
| Delta-He (pg) | 2.3 (0.9–3.9) | 3.1 (2.3–3.7) |
| Ret-He (pg) | 34.0 (32.4–36.3) | 33.8 (32.0–36.0) |
| S-ferritin (μg/L) | 299 (179–538) | 42 (23–82) |
| Transferrin saturation (%) | 26 (19–35) | – |
| EHRI (IU/kg/g/L Hb per week) | 0.65 (0.26–0.89) | – |
| P-interleukin-6 (pg/mL) | 6.5 (3.9–9.6) | NA |
| P-tumour necrosis factor (pg/mL) | 16.7 (14.7–18.6) | NA |
| P-parathyroid hormone (pg/mL) | 281 (146–443) | NA |
| Medication use (%) | ||
| Antihypertensive drugs | 91 | – |
| Statins | 49 | |
| Antiaggregants/anticoagulants | 49 | |
| Erythropoietin-stimulating agents | 93 | |
| Phosphate binders | 72 | |
| Vitamin D receptor activators | 83 | |
| Calcimimetics | 12 | |
| Immunosuppressant drugs | 13 | |
| Iron supplementation (intravenous or oral) | 32 | |
Categorical data are shown as percentage; continuous data as mean ± SD or median and interquartile range (25th and 75th percentiles) as appropriate.
NA, not available.
aVintage denotes preceding total time on PD.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
